Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden.

Regen Biotech Co., Ltd. is a private company headquartered in the South Korea. The firm engages in biotechnology company.

Hangzhou Huadi Group Co., Ltd., established on 2011-02-10, Business scope includes operations without storage(Wholesale without warehousing)other hazardous chemicals:phenol,ethanol[Anhydrous](For details, see<Hazardous Chemical Business License>)Serve:Pharmaceutical Intermediates,medical technology,Technological Development of Agricultural Technology,Technical Services,technical consulting,Achievement transfer,Economic Information Consulting(In addition to commodity intermediary);wholesale,retail:electronic product,communication equipment(In addition to exclusive control),Telecommunications equipment,medical instruments(Limited to one category,Class II),Pharmaceutical Intermediates,chemical reagent(In addition to chemical dangerous goods and the first category of precursor chemicals),cosmetic,food additives,Primary Edible Agricultural Products(except food,medicine),clothing;Acquisition of primary edible agricultural products required for sales by the enterprise(except food,medicine,Limited to direct purchases from original producers in the primary industry);Import and export,Technology Import and Export(National law,Except for items prohibited by administrative regulations,law,Projects restricted by administrative regulations can only be operated after obtaining a license);Realtor;Including the business scope of subordinate branches.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Repro-Med Systems, Inc. engages in the design, manufacture, and market of proprietary medical devices. Its product portfolio includes FREEDOM60, FreedomEdge syringe drivers, Precision Flow Rate Tubing, and HIgH-Flo Subcutaneous Safety Needle Sets. The company was founded by Andrew I. Sealfon and Adrian W. Zorgniotti on March 24, 1980 and is headquartered in Mahwah, NJ.

Koyo Corp. is a Japanese private company located in Tokyo that functions as an investment holding company whose subsidiary provides real estate services.

Laboratorios Indas, S.A.U. manufactures sanitary and hygienic products for urinary incontinence applications. It offers pads, bed protectors, light incontinence pads, protective and healing creams, protective moisturizing oils, wet towels, mitts, ankle and elbow protectors, healing gels, baby diapers, baby wet wipes, intimate wipes, and sanitary towels. The company also provides pantiliners, cotton and cellulose obstratic pads, breastfeeding pads, make-up remover towels, refreshing wipes, hand cleaning wipes, sterile gauze dressings for use in cures, dressing for tracheotomized patients, stretch crepe bandages, cotton wools, and cosmetic cottons. It offers its products to consumers, patients

Toray Industries, Inc. (東レ株式会社 Tōre Kabushiki-gaisha) is a multinational corporation headquartered in Japan that specializes in industrial products centered on technologies in organic synthetic chemistry, polymer chemistry, and biochemistry.

Wuxi Kailida Industrial Co., Ltd., established on 1998-04-28, Business scope includes0.01%Production of triptolide parent drug;0.25mg/Processing of kilogram triptolide granules;Tripterygium wilfordii extract(Does not contain dangerous goods),Latex wrapping cloth,bring,coated mesh,cable filling material,Fiberglass products,Manufacture of Plastic Products,processing;Planting of fruit seedlings,Sales and technical consulting services;Acquisition of agricultural by-products(Does not contain grain,cotton,Silkworm cocoons);road general cargo transportation;own property rental.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Highland Innovation Centre Ltd (HIC) is a Scottish-based Medical Scientific device company which specialises in the design, development and commercialisation of consumer, clinical and research products.

TranXenoGen, Inc is a publicly traded biotechnology company listed on the Alternative Investment Market of the London Stock Exchange (TXN.L). The Company is focused on developing new methods for manufacturing therapeutic proteins and a portfolio of products. Its product pipeline includes Anti-Neoplastic Urinary Protein ("ANUP") for the treatment of several types of cancer, Insulin and Human Serum Albumin ("HSA"). The Company believes that its technology platform willhave multiple applications including the generation of transgenic chickensfor the manufacture of high volume therapeutic proteins, animal models forthe study of disease, and high throughput production of antibodies fromgenomic derived targets for product identification. TranXenoGen isdeveloping itstechnologyplatform for the production of generic biologicals(e.g., Insulin and HSA), contract manufacturing of third party products andpotential applications in the areas of biodefense and vaccine development.In addition, the Company is exploring licensing of both the technology andproducts for certain geographic areas and commercial applications.

Izumi Techno is a retail company that provides cleaning, repairs, and renewals services.

BioMerieux designs, develops, manufactures, and markets in vitro diagnostic systems for clinical and industrial applications. The company’s diagnostic systems consist of reagents and consumables used to conduct biological tests, for use in performing screening, diagnostic assistance, prognosis, and treatment monitoring; instruments, platforms, and autoanalyzers used for automated testing at high or low throughputs; software to process analyses and systems to interpret biological test results; and other related services such as the installation and maintenance of instruments, user training, and the audit of laboratory workflows. BioMerieux offers diagnostic systems for clinical applications including the diagnosis of infectious diseases, comprising HIV, tuberculosis, and respiratory diseases, as well as cardiovascular diseases and targeted cancers based on the analysis of biological samples such as blood, saliva, and urine; and for industrial applications including the analysis of microbiological manufacturing such as food, pharmaceuticals, and cosmetics. The company markets and sells its products through a network of distributors to private sector analysis laboratories, hospital laboratories, blood banks, and physician office laboratories; food, pharmaceutical, and cosmetics industries; and independent quality control laboratories. It has operations in Europe, the Middle East, Africa, North America, Asia-Pacific, and Latin America. BioMerieux were founded in 1963 and is headquartered in Marcy l’Etoile, France. It is a subsidiary of Institut Mérieux.

ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

MBN Nanomaterialia offers new highly-technological raw materials, with singular characteristics, suitable to be transformed into goods/components through the traditional manufacturing industrial routes, favoring both quick product innovations and unique solutions. MBN offers innovative materials and technical solutions that are the direct outcome of scientific and technological research initiatives performed in collaboration with Universities, Research Institutes and Industries at national and European level. MBN is author of many scientific articles and owns several patents. The company, through its President, chairs the European Nanotechnology Platform (Nanofuture).

Inner Mongolia Mengti Biological Engineering Co., Ltd., established on 2015-09-10, Business scope includes technology research and development of biochemical products;Engineering and Technology Research and Experimental Development;Cosmetics Wholesale;internet sales(Except for products that require a license for sale);Sales of hygiene products and single-use medical products;Daily necessities sales;Chinese herbal medicine planting;Chinese herbal medicine acquisition;General merchandise sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Disinfectant sales(Free of Hazardous Chemicals);General Cargo Warehousing Services(Does not contain hazardous chemicals and other items that require approval);Conference and Exhibition Services;market survey(Does not include foreign investigations);sales agent;Healthy food(prepackaged)Sales;Sales of infant formula milk powder and other infant formula food;Sales of formula food for special medical purposes;Medical Research and Experimental Development;food production;food sales;Health food production;pharmaceutical production;Drug Wholesale;Cosmetic production;Drug internet information service;Class III medical device business;Internet information service;Infant formula production;Production of formula food for special medical purpose;Pharmaceutical commissioned production